Barriers and facilitators of use of hydroxyurea among children with Sickle Cell Disease: Experiences of stakeholders in Tanzania

dc.contributor.authorKilonzo, M.
dc.contributor.authorChilande, L.
dc.contributor.authorMinja, I.K.
dc.contributor.authorBalandya, E.
dc.contributor.authorRuggajo, P.
dc.date.accessioned2022-10-11T07:27:09Z
dc.date.available2022-10-11T07:27:09Z
dc.date.issued2021
dc.description.abstractFactors contributing to low use of HU among SCD patients exist in high-income countries. The latter leaves a drift of literature on factors for low utilization of HU in developing countries. This study aimed to explore the factors influencing the use of HU in the management of SCD in Tanzania. A qualitative study was employed to interview purposively selected participants for this study. The in-depth interviews were conducted with 11 parents of children with SCD, four medical doctors working at sickle cell clinics, and two representatives of the national health insurance fund (NHIF). Interviews were audio-recorded, transcribed, and thematically analysed. Barriers identified were misconception of parents on SCD, financial constraints, regulatory restrictions, worries and fears of medical doctors on the acceptability of HU, shortages of laboratory equipment and consumables, and limited availability of HU. Adequate knowledge of the parents and medical doctors on SCD and HU and opportunities for HU accessibility were the facilitators identified. The utilization of HU by the individual with SCD is affected by several factors, from individual to policy level. Nevertheless, parents of children with SCD and medical doctors working in sickle cell clinics demonstrated good knowledge of the diseases and HU.en_US
dc.identifier.citationKilonzi, M.; Mlyuka, H.J.; Felician, F.F.; Mwakawanga, D.L.; Chirande, L.; Myemba, D.T.; Sambayi, G.; Mutagonda, R.F.; Mikomangwa, W.P.; Ndunguru, J.; et al. Barriers and Facilitators of Use of Hydroxyurea among Children with Sickle Cell Disease: Experiences of Stakeholders in Tanzania. Hemato 2021, 2, 713–726. https://doi.org/10.3390/ hemato2040048en_US
dc.identifier.urihttp://dspace.muhas.ac.tz:8080/xmlui/handle/123456789/2985
dc.language.isoenen_US
dc.subjectHydroxyurea; barriers; facilitators; utilizationen_US
dc.titleBarriers and facilitators of use of hydroxyurea among children with Sickle Cell Disease: Experiences of stakeholders in Tanzaniaen_US
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Kilonzo, 2021.pdf
Size:
253.34 KB
Format:
Adobe Portable Document Format
Description:

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.63 KB
Format:
Item-specific license agreed upon to submission
Description: